688016 Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.
- 116.27
- -2.02-1.71%
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. News
Shanghai MicroPort Endovascular MedTech Obtains Medical Device Registration for Catheter
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH): The peripheral balloon dilation catheter has obtained the medical instruments registration certificate.
According to Gelonghui on December 18, Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH) announced that its holding subsidiary, Shanghai Lanmai Medical Technology Co., Ltd., has obtained the medical instruments registration certificate issued by the National Medical Products Administration, with the product name: peripheral balloon dilatation catheter. The acquisition of this medical instruments registration certificate further enriches the existing product categories of the company, expands the company's product line layout in the peripheral vein field, further promotes the company's market expansion in the peripheral field, continuously meets market demands, drives steady growth in the company's overall sales revenue and profit, and deepens the company's presence in the aortic and peripheral vascular intervention market.
Retail Investors Are Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥660m Last Week
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) plans to launch an employee stock ownership plan in 2024.
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced the 2024 employee stock ownership plan (draft), the employee stock ownership plan...
Shanghai MicroPort Endovascular MedTech to Pay Up to 70 Million Yuan in Back Taxes
shanghai microport endovascular medtech(group)co.,ltd. may need to pay 70 million in back taxes after being disqualified as a high-tech enterprise.
shanghai microport endovascular medtech(group)co.,ltd. needs to pay up to 70 million yuan in back taxes due to the cancellation of its high-tech enterprise qualification certification, which is expected to account for more than 10% of the net income in the most recent fiscal year. shanghai microport endovascular medtech(group)co.,ltd. stated that it is currently communicating with relevant units regarding this matter; In addition, shanghai microport endovascular medtech(group)co.,ltd. previously revealed that without considering the impact of non-operating risk factors, the projected growth of the attributable net income in 2024 is around 0-10%.
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) spent 99.9889 million yuan to complete the repurchase of 0.88% of the shares.
Shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced that as of the date of this announcement, the company has completed this repurchase. The company...
HK stocks unusual movement | microport (00853) rose nearly 8% intraday shanghai microport endovascular medtech(group)co.,ltd. net income increased by over 42% in the first three quarters. Morgan Stanley raised the company's long-term net income forecast.
Microport (00853) rose nearly 8% intraday, as of the time of publication, up 4.1% to HK$6.86, with a turnover of 96.2774 million Hong Kong dollars.
Shareholders In Shanghai MicroPort Endovascular MedTech (SHSE:688016) Should Look Beyond Earnings For The Full Story
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH): In October, the company did not repurchase A-shares through centralized auction trading.
On November 4th, Ge Longhui reported that shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced that in October 2024, the company did not repurchase A-shares through centralized bidding trading. As of October 31, 2024, the company has repurchased a total of 894,027 shares through the Shanghai Stock Exchange exchange trading system by centralized bidding trading method, accounting for 0.73% of the company's total share capital of 123,262,117 shares. The highest price for repurchase was 98.13 yuan/share, the lowest price was 78.69 yuan/share, and the total amount paid was RMB 79,989,242.97 (excluding prin
Shanghai MicroPort Endovascular MedTech Co., Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced a half-year equity distribution for 2024: a dividend of 1.66205 yuan per share, with the record date of November 7th.
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) issued the 2024 interim equity distribution announcement to implement the 2024 interim...
Cardiac Healthcare: third quarter report 2024
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH): net income in the first three quarters was 0.553 billion yuan, a year-on-year increase of 42.46%.
GeLongHui October 29th | shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced its third-quarter report, with a revenue of 0.97 billion yuan in the first three quarters, a year-on-year increase of 9.13%, a net income of 0.553 billion yuan, a year-on-year increase of 42.46%, a non-GAAP net income of 0.5 billion yuan, a year-on-year increase of 37.37%, and basic earnings per share of 4.49 yuan.
Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) Surges 37% Yet Its Low P/E Is No Reason For Excitement
MicroPort Endovascular MedTech Affiliates Get China Nod for Blood Vessel Repair Devices
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH): obtained medical instruments registration certificate
The shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced on September 23 that its holding subsidiary, Shanghai Hongmai Medical Technology Co., Ltd., has obtained the medical instrument registration certificate for fiber occluder spring coils issued by the National Medical Products Administration. The company's representative, Veryan Medical Ltd.'s product, has obtained the medical instrument registration certificate for the peripheral brackets system, BioMimics 3D Stent System, issued by the National Medical Products Administration. The acquisition of the above-mentioned medical instrument registration certificates further enriches the company's existing product categories and expands the company.
Is Weakness In Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Shanghai Microport Endovascular Medtech(Group)Co.,Ltd.(688016.SH): has accumulated repurchased 0.71% of shares.
As of August 31, 2024, Shanghai Microport Endovascular Medtech(Group)Co.,Ltd.(688016.SH) announced that the company has repurchased a total of 880,390 shares through the Shanghai Stock Exchange trading system through centralized bidding trading, accounting for 0.71% of the company's total share capital of 123,262,117 shares. The highest repurchase price was 98.13 yuan/share, and the lowest price was 78.69 yuan/share. The total amount paid was RMB 78,902,279.90 (excluding stamp duty, transaction commission, and other transaction fees).
MicroPort: Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.'s net income attributable to shareholders in the first half of the year was CNY 0.404 billion, a year-on-year increase of 44.36%.
Microport (00853) has released unaudited financial data for its subsidiary, Shanghai Microport Endovascular Medtech(Group)Co.,Ltd., for the six months ending June 30, 2024. Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. achieved revenue of RMB 0.787 billion, a year-on-year increase of 26.63%; and net income attributable to shareholders of Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. was RMB 0.404 billion, a year-on-year increase of 44.36%.
No Data
